Avidity Biosciences (RNA) Payables (2019 - 2025)
Historic Payables for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $9.6 million.
- Avidity Biosciences' Payables fell 8060.37% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 8060.37%. This contributed to the annual value of $8.5 million for FY2024, which is 7536.18% down from last year.
- Per Avidity Biosciences' latest filing, its Payables stood at $9.6 million for Q3 2025, which was down 8060.37% from $3.9 million recorded in Q2 2025.
- Avidity Biosciences' Payables' 5-year high stood at $54.2 million during Q1 2025, with a 5-year trough of $3.9 million in Q2 2025.
- Its 5-year average for Payables is $25.2 million, with a median of $26.4 million in 2022.
- Its Payables has fluctuated over the past 5 years, first soared by 14071.21% in 2022, then tumbled by 9043.59% in 2025.
- Avidity Biosciences' Payables (Quarter) stood at $14.1 million in 2021, then surged by 131.25% to $32.6 million in 2022, then grew by 5.43% to $34.3 million in 2023, then plummeted by 75.36% to $8.5 million in 2024, then grew by 13.77% to $9.6 million in 2025.
- Its Payables was $9.6 million in Q3 2025, compared to $3.9 million in Q2 2025 and $54.2 million in Q1 2025.